Search research articles
Contact Us
Filters
Showing results (291-300 of 319) with videos related to
Page
of 32
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 21, 2010
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses
Jeffrey L Lennox, Edwin Dejesus, Daniel S Berger, et al.
Archives of Internal Medicine
|
January 25, 2006
Assessing the performance of overseas tuberculosis screening programs: a study among US-bound immigrants in Vietnam
Susan A Maloney, Katherine L Fielding, Kayla F Laserson, et al.
Hepatology Communications
|
May 16, 2018
Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection
Jacob George, Eduard Burnevich, I-Shyan Sheen, et al.
Biorxiv : the Preprint Server for Biology
|
March 3, 2023
Three-Dimensional Bioconjugated Liquid-Like Solid (LLS) Enhance Characterization of Solid Tumor - Chimeric Antigen Receptor T cell interactions
Duy T Nguyen, Ruixuan Liu, Elizabeth Ogando-Rivas, et al.
Acta Biomaterialia
|
October 3, 2023
Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions
Duy T Nguyen, Ruixuan Liu, Elizabeth Ogando-Rivas, et al.
The Lancet. HIV
|
September 19, 2017
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
Pedro Cahn, Richard Kaplan, Paul E Sax, et al.
Journal of Hepatology
|
August 21, 2016
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial
Jan Sperl, Gabor Horvath, Waldemar Halota, et al.
The Journal of Pharmacy Technology : Jpt : Official Publication of the Association of Pharmacy Technicians
|
May 16, 2022
Pharmacists' Perspectives on the Use of Telepharmacy in Response to COVID-19 Pandemic in Ho Chi Minh City, Vietnam
Truong Van Dat, Trung Dinh Tran, Nguyen Thao My, et al.
Blood
|
December 17, 2025
The glycosaminoglycan oncofetal chondroitin sulfate represents a novel target for antibody drug-conjugate therapy for AML
Joana Mujollari, Montserrat Estruch Alrich, Priya Khadgawat, et al.
Medicine
|
April 26, 2024
Prognostic values of serum lactate-to-bicarbonate ratio and lactate for predicting 28-day in-hospital mortality in children with dengue shock syndrome
Thanh Nguyen Tat, Nhu Vo Hoang-Thien, Dat Nguyen Tat, et al.
Page
of 32
Search research articles
Search
Showing results (291-300 of 319) with videos related to
Sort By:
Page
of 32
Journal of Acquired Immune Deficiency Syndromes (1999)
|
April 21, 2010
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses
Jeffrey L Lennox, Edwin Dejesus, Daniel S Berger, et al.
Archives of Internal Medicine
|
January 25, 2006
Assessing the performance of overseas tuberculosis screening programs: a study among US-bound immigrants in Vietnam
Susan A Maloney, Katherine L Fielding, Kayla F Laserson, et al.
Hepatology Communications
|
May 16, 2018
Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection
Jacob George, Eduard Burnevich, I-Shyan Sheen, et al.
Biorxiv : the Preprint Server for Biology
|
March 3, 2023
Three-Dimensional Bioconjugated Liquid-Like Solid (LLS) Enhance Characterization of Solid Tumor - Chimeric Antigen Receptor T cell interactions
Duy T Nguyen, Ruixuan Liu, Elizabeth Ogando-Rivas, et al.
Acta Biomaterialia
|
October 3, 2023
Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions
Duy T Nguyen, Ruixuan Liu, Elizabeth Ogando-Rivas, et al.
The Lancet. HIV
|
September 19, 2017
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
Pedro Cahn, Richard Kaplan, Paul E Sax, et al.
Journal of Hepatology
|
August 21, 2016
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial
Jan Sperl, Gabor Horvath, Waldemar Halota, et al.
The Journal of Pharmacy Technology : Jpt : Official Publication of the Association of Pharmacy Technicians
|
May 16, 2022
Pharmacists' Perspectives on the Use of Telepharmacy in Response to COVID-19 Pandemic in Ho Chi Minh City, Vietnam
Truong Van Dat, Trung Dinh Tran, Nguyen Thao My, et al.
Blood
|
December 17, 2025
The glycosaminoglycan oncofetal chondroitin sulfate represents a novel target for antibody drug-conjugate therapy for AML
Joana Mujollari, Montserrat Estruch Alrich, Priya Khadgawat, et al.
Medicine
|
April 26, 2024
Prognostic values of serum lactate-to-bicarbonate ratio and lactate for predicting 28-day in-hospital mortality in children with dengue shock syndrome
Thanh Nguyen Tat, Nhu Vo Hoang-Thien, Dat Nguyen Tat, et al.
Page
of 32